vimarsana.com

Page 46 - நிறுவனம் ஆஃப் புற்றுநோய் ஆராய்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Early findings show new drug could be game-changing for brain cancer treatment | Cancer research

Hamish Mykura, 59, from West Sussex, has seen his tumour disappear from scans. He was diagnosed with glioblastoma in August 2018 and was referred to the Royal Marsden for treatment, which included chemotherapy and radiotherapy, with surgery at St George’s hospital. When the treatment stopped working and the cancer started to grow in August 2019, he joined the Ice-Cap trial. Twenty months on, Hamish has no visible cancer. “The emotional journey I have been on over the last few years has been dramatic and, considering the seriousness of my diagnosis, it’s astonishing that I’m still here,” he said. “In fact, a few months into the trial it felt like all hope had gone as it appeared my cancer had started growing again. However, surgery revealed the growth was actually inflammation caused by the drugs attacking the tumour – they were working. Ever since, I’ve been in a great position with scans indicating my cancer is stable.

Early findings show new drug could be game-changing for brain cancer treatment

Early findings show new drug could be ‘game-changing’ for brain cancer treatment Sarah Boseley Two people with advanced brain cancer of the sort that led to the death of the MP Tessa Jowell have responded well in a small trial to an experimental combination of chemo and immunotherapy drugs. In one case, the life-threatening tumour seems to have disappeared. Doctors at the Institute of Cancer Research and the Royal Marsden hospital in London cautioned that this was very early research but said it was unusual to have such a good response in patients in an early trial. Ten patients were enrolled in the phase I trial called Ice-Cap. They had advanced glioblastoma, a tumour in the brain similar to that which also killed US president Joe Biden’s son, Beau.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.